Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 1, 2023 (4 years ago)

Heparin Sodium (Heparin Sodium and Dextrose)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Subpotent Drug: low Anti-Factor IIa potency.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Heparin Sodium, 25,000USP units per 250 mL, (100 USP units per mL) in 5% Dextrose Injection, 250 mL Excel Container, B.Braun Medical Inc, Bethlehem, PA. 18018-3524 USA. NDC 0264-9587-20.

Affected NDC 0264-9587-20

Compare with the code on your package — it is the most precise check available.

Drug: Heparin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Heparin Sodium in Dextrose
Heparin Sodium and Dextrose
NDC 00264-9587
HEPARIN SODIUM 10000 [USP'U]/100mL; DEXTROSE MONOHYDRATE 5 g/100mL Injection
Intravenous
B. Braun Medical Inc. Rx
Recalling firm
B. Braun Medical Inc
NDC code
0264-9587-20
Origin
CA, United States
FDA recall number
D-0434-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Heparin recalls

See all

Other recalls by B. Braun Medical Inc

All 2023 recalls